Provided by Tiger Trade Technology Pte. Ltd.

Rocket Pharmaceuticals, Inc.

3.53
+0.11503.37%
Volume:1.29M
Turnover:4.50M
Market Cap:386.96M
PE:-20.74
High:3.57
Open:3.56
Low:3.40
Close:3.41
52wk High:5.45
52wk Low:2.53
Shares:109.77M
Float Shares:84.96M
Volume Ratio:1.90
T/O Rate:1.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1700
EPS(LYR):-2.0100
ROE:-4.77%
ROA:-28.42%
PB:1.05
PE(LYR):-1.75

Loading ...

Needham Upgrades Rocket Pharmaceuticals to Buy From Hold, Price Target is $9

MT Newswires Live
·
Yesterday

Rocket Pharmaceuticals upgraded to Buy from Hold at Needham

TIPRANKS
·
Yesterday

Rocket Pharmaceuticals is Maintained at Buy by Chardan Capital

Dow Jones
·
Sep 15

Rocket Pharma Shares Climb Premarket After FDA Supports Continuation of Trial

Dow Jones
·
Sep 15

Rocket Pharmaceuticals Says FDA Confirms Path to Complete Phase 2 Danon Disease Trial

MT Newswires Live
·
Sep 15

Rocket Pharmaceuticals, - FDA Confirms 12-Month Co-Primary Endpoints for Potential Accelerated Approval

THOMSON REUTERS
·
Sep 15

Rocket Pharmaceuticals, - Expects to Complete Rp-A501 Dosing by Mid-2027

THOMSON REUTERS
·
Sep 15

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of Rp-A501 in Danon Disease

THOMSON REUTERS
·
Sep 15

Rocket Pharmaceuticals, - FDA Confirms Pivotal Efficacy Population of 12 Patients for Rp-A501 Trial

THOMSON REUTERS
·
Sep 15

Q32 Bio Names José Trevejo Chief Medical Officer

Reuters
·
Sep 14

Rocket Pharma to Present at Cantor Global Healthcare Conference

Reuters
·
Sep 03

Rocket Pharmaceuticals Price Target Maintained with a $11.00/Share by Chardan Capital

Dow Jones
·
Sep 01

Rocket Adopts Severance, Change-in-Control Program for US Employees, Executives

Reuters
·
Aug 28

Don't Ignore The Insider Selling In Rocket Pharmaceuticals

Simply Wall St.
·
Aug 15

MacroGenics Q2 Revenue Misses Estimates, Posts Profit on Asset Sale

Reuters
·
Aug 14

MeiraGTx Q2 Revenue Jumps on Reogen License Revenue

Reuters
·
Aug 13

Rocket Pharmaceuticals, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Abeona Therapeutics Q2 Net Loss Widens, Misses Analyst Expectations

Reuters
·
Aug 13

Rocket Pharmaceuticals' Danon, PKP2-ACM Updates Seen as Key H2 Catalysts, Wedbush Says

MT Newswires Live
·
Aug 12

Rocket Pharmaceuticals Price Target Cut to $15.00/Share from $16.00 by Wedbush

Dow Jones
·
Aug 11